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Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium
terrae in a Patient with Bronchiectasis
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We report a rare case of lung disease caused by Mycobacterium terrae in a previously healthy woman. A 45-year-old 
woman was referred to our hospital due to a chronic cough with sputum. A computed tomography scan of the 
chest revealed bronchiolitis in conjuction with bronchiectasis in both lungs. Nontuberculous mycobacteria were 
identified and isolated from the bronchoalveolar lavage fluid collected from each lung. All isolates were identified 
as M. terrae by various molecular methods that characterized the rpoB and hsp65 gene sequences. Antibiotic 
therapy using clarithromycin, rifampin, and ethambutol improved the patient's condition and successfully resulted 
in sputum conversion.
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Introduction
  Mycobacterium terrae complex is known to comprise 
multiple species, including M. terrae, M. non-
chromogenicum, and M. trivia1. M. terrae is ubiquitous 
in the environment and generally considered a non-
pathogenic nontuberculous mycboacteria (NTM)1. The 
most common presentation of M. terrae infection is te-
nosynovitis of the upper extremities, often following 
trauma2,3. To date, few cases of NTM lung disease 
caused by M. terrae have been reported. Here, we re-
port a very rare case of M. terrae lung disease asso-
ciated with bronchiectasis in an immunocompetent 
patient.
Case Report
  In March 2008, a 45-year-old woman was referred to 
our hospital due to chronic cough and sputum. The pa-
tient had been healthy until two months earlier, when 
cough and purulent sputum developed. She had a his-
tory of smoking (10 pack-years), but had stopped 10 
years prior. The patient had pectus excavatum. Labora-
tory results were normal with the exception of elevated 
CA 19-9 (75.32 U/mL, normal range, 0∼37 U/mL). Her 
height was 161 cm and body weight was 51 kg. A hu-
man immunodeficiency virus (HIV) antibody test was 
negative.
  A computed tomography (CT) scan of the chest re-
vealed bronchiectasis and bronchiolitis in both lungs 
(Figure 1A). The patient also had pectus excavatum in 
the anterior chest wall. There was no evidence of cystic 
fibrosis or other common causes of bronchiectasis. NTM 
were isolated from bronchoalveolar lavage fluid col-
lected from both lungs and cultured in vitro.
  Polymerase chain reaction (PCR) restriction fragment 
length polymorphism analysis (PRA) was used to identi-
fy the particular mycobacterial species isolated from the 
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Figure 1. A 45-year-old woman with bronchiectasis and nontuberculous mycobacterial lung disease caused by 
Mycobacterium terrae. (A) A transverse CT scan (2.5-mm-section thickness) obtained on level with the right inferior
pulmonary vein at the time of presentation, before treatment, reveals bilateral bronchiectasis (arrows) in the right middle
lobe and the lingular segment of the left upper lobe, as well as cellular bronchiolitis with tree-in-bud signs (black arrow
heads) in both lungs. Lobular consolidation in the right middle lobe (white arrow heads) was also noted. (B) A CT scan
of the same patient after 12 months of antibiotic therapy revealed a decrease in the extent of cellular bronchiolitis and
lobular consolidation in both lungs. CT: computed tomography.
Figure 2. Electrophoresis of the PCR restriction enzyme
PRA of the rpoB and hsp65 genes from the clinical isolate
of the patient. M, size marker; Lane 1, rpoB gene PCR
product after digestion by MspI Lane 2, PCR product of
the rpoB gene after digestion by Hae III Lane 3, PCR 
product of the hsp65 gene after digestion by Hae III. 
PCR: polymerase chain reaction; PRA: polymorphism 
analysis.
patient. DNA was extracted from pure culture colonies 
of mycobacteria grown on 7H10-OADC agar plate and 
the genes rpoB and hsp65 were amplified by PCR. PCR 
product was digested using the restriction enzymes 
MspI and HindIII as described previously4,5. The pattern 
of the resulting DNA fragments was then compared to 
those kept in a database of known mycobacterial 
species. PRA of the rpoB gene resulted in fragment 
lengths of 110, 95, 55, and 45 bp using Msp I and 175, 
55, and 45 bp using Hae III (Figure 2). These DNA frag-
ment lengths matched the known restriction fragment 
patterns of the reference strain of M. terrae ATCC15755 
reported in the previous studies5,6. The identity of etio-
logical agent was also confirmed by sequencing analy-
sis, revealing 99 and 100% sequence similarity with the 
rpoB gene (GenBank accession no. AF057488.1) and 
hsp65 gene (GenBank accession no. AF547879) of M. 
terrae ATCC15755, respectively.
  Drug susceptibility testing was performed using a 
broth microdilution method, as previously described for 
slow growing mycobacteria, such as M. kansasii, ac-
cording to the guidelines of the Clinical and Laboratory 
Standards Institute (CLSI)7. The clinical isolate of M. ter-
rae was susceptible to clarithromycin, ethambutol, and 
amikacin but resistant to ciprofloxacin and rifampin 
(Table 1).
  The patient was treated with oral clarithromycin (1,000 
mg/day), rifampin (600 mg/day), and ethambutol (800 
mg/day) for 18 months. The treatment outcome was fa-
vorable; the patient's symptoms resolved completely, ra-
diographic findings improved (Figure 1B), and negative 
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Table 1. Antimicrobial susceptibility patterns for the 
Mycobacterium terrae strain isolated from our patient
Antimicrobial agent MIC (μg/mL) Interpretation
Clarithromycin ≤0.5 Susceptible
Rifampin    2   Resistant
Ethambutol  2   Susceptible
Amikacin    4   Susceptible
Ciprofloxacin 8   Resistant
Moxifloxacin  2   Intermediate
MIC: minimum inhibitory concentration.
conversion of sputum cultures was achieved and main-
tained after 12 months of antibiotic therapy (Figure 1B).
Discussion
  Despite the prevailing view that M. terrae complex 
isolates are nonpathogenic, these organisms are occa-
sionally identified in clinical specimens8. For example, 
in our institution, M. terrae complex made up 3% of 
1,548 NTM clinical isolates during the 2-year period 
from 2002 to 20039. Nonetheless, no patient had clin-
ically significant disease caused by M. terrae complex 
infection during that time.
  NTM lung disease caused by M. terrae complex is 
rarely reported in the literature10-12, and there is no re-
ported case in Korea. Furthermore, previous studies 
have had difficulty identifying the exact species of clin-
ical isolates, as commercial DNA probes and high per-
formance liquid chromatography (HPLC) are not suit-
able methods to distinguish between different member 
species of the M. terrae complex. A recent study analyz-
ing 16S rRNA and hsp65 genes demonstrated genomic 
heterogeneity among M. terrae complex members13. 
Therefore, we were able to confirm that our patient had 
M. terrae infection using modern molecular techniques 
that enabled sequencing of the rpoB and hsp65 genes.
  NTM lung disease has two distinct radiographic mani-
festations: an upper lobe fibrocavitary form and a nod-
ular bronchiectatic form1. The nodular bronchiectatic 
form of the disease occurs predominantly in non-
smoking middle-aged or elderly women who have no 
underlying lung disease. The radiographic features of 
the nodular bronchiectatic form include bronchiectasis 
and multiple nodules, which tend to be most severe in 
the lingular segment of the left lung and in the right 
middle lobe. These features are well characterized in 
M. avium complex lung disease, but have also been 
noted in NTM lung disease caused by other NTM spe-
cies, such as M. abscessus complex14-16. In addition, 
women with the nodular bronchiectatic form of NTM 
lung disease also often have certain medical conditions, 
including pectus excavatum, scoliosis, and thin body 
habitus17. Our case study presented with typical clinical 
and radiographic features of the nodular bronchiectatic 
form of NTM lung disease.
  The optimal antimicrobial therapy regimen for M. ter-
rae infection has yet to be established. Some have sug-
gested that drug treatment regimen for M. terrae in-
fection should include macrolide, rifampin, and etham-
butol2. Our patient received these three drugs and had 
substantial improvement without significant sequelae. 
Despite the rifampin resistant that the clinical isolates 
exhibited in vitro, it was included in the treatment regi-
men for our patient. It is unclear whether the combina-
tion of rifampin and ethambutol proved an additive, or 
synergistic, effect2.
  In conclusion, M. terrae should be considered a pos-
sible etiologic pathogen of the nodular bronchiectatic 
form of NTM lung disease, despite the rare occurrence 
of M. terrae lung disease. Additionally, macro-
lide-containing antibiotic therapies may be effective in 
the treatment of M. terrae lung disease.
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